Background: Fungal infection especially mucormycosis seems remarkably upsurged in theCOVID era, especially during the 2nd wave peak of the pandemic raising the concern of the clinician for the admitted patient. Steroid therapy, diabetes and other immunocompromised states whenever associated more commonly involved with Covid Associated Mucormycosis(CAM). Aim and Objective: To determine the prevalence of mucormycosis during the second wave of the COVID-19 pandemic and identify the risk factors associated with the same. Methodology: Samples were received in the microbiology lab from all clinically suspected mucormycosis patients during 2nd peak process for KOH wet mount, fungal culture in SDA and COVID RTPCR testing. All relevant clinical and associated risk factors were tabulated and analysed.